Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065318 | 0.86 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL14137024 | 0.85 | HTR2A (0.81) | HTR2AHTR2C | |
| SCHEMBL29573467 | 0.84 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL14067169 | 0.84 | HTR2A (0.61) | HTR2AHTR2C | |
| SCHEMBL1165808 | 0.84 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL22825434 | 0.84 | HTR2A (0.72) | HTR2AHTR2C | |
| SCHEMBL1167170 | 0.83 | HTR2A (0.60) | HTR2AHTR2C | |
| SCHEMBL2064347 | 0.83 | KDM4C (0.51) | HTR2AHTR2C | |
| SCHEMBL18085715 | 0.83 | HTR2A (0.60) | HTR2AHTR2C | |
| SCHEMBL5578053 | 0.82 | HTR2A (0.63) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138784-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-05-07 | — | — | US | claimed |
| US-10071075-B2 | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2018-09-11 | — | — | US | claimed |
| US-20180072680-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | claimed |
| US-9353064-B2 | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | claimed |
| US-9126946-B2 | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | claimed |
| US-20150210648-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-07-30 | — | — | US | claimed |
| US-20110207790-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | claimed |
| WO-2010062321-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20220160681-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220160681-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20200397753-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200397753-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200397755-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| EP-1695966-A1 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006081335-A2 | PROCESS FOR PREPARING SUBSTITUTED 1- [3- ( PYRAZOLYL) PHENYL] -3-PHENYL UREAS | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1558582-B1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1558582-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTIALS, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005012254-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397755-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885 |
| US-20150210648-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | REN, UACA, IPO4 | HTR2A 4233/4885HTR2C 2559/4885 |
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885 |
| US-10071075-B2 | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto | REN, UACA, IPO4 | HTR2A 4233/4885HTR2C 2559/4885 |
| US-20200397753-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885 |
| US-20180072680-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | IPO4, REN, UACA | HTR2A 4311/4885HTR2C 2632/4885 |
| US-20220160681-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885 |
| US-20110207790-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)UREA AND CRYSTALLINE FORMS RELATED THERETO | IPO4, USO1, UACA | HTR2A 4375/4885HTR2C 2675/4885 |
| US-20200138784-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | REN, UACA, IPO4 | HTR2A 4233/4885HTR2C 2559/4885 |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.